 Bradley Haverkos
Concepts (162)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Extranodal NK-T-Cell | 3 | 2020 | 7 | 2.050 |
Why?
| | Lymphoma, T-Cell, Cutaneous | 5 | 2020 | 37 | 1.800 |
Why?
| | Herpesvirus 4, Human | 5 | 2018 | 148 | 1.640 |
Why?
| | Hematopoietic Stem Cell Transplantation | 9 | 2020 | 563 | 1.620 |
Why?
| | Lymphoma, T-Cell | 5 | 2022 | 17 | 1.600 |
Why?
| | Lymphoma | 4 | 2022 | 180 | 1.410 |
Why?
| | Transplantation Conditioning | 9 | 2020 | 178 | 1.310 |
Why?
| | Programmed Cell Death 1 Receptor | 3 | 2018 | 188 | 1.290 |
Why?
| | Hodgkin Disease | 2 | 2018 | 115 | 1.180 |
Why?
| | Hematopoietic Stem Cell Mobilization | 2 | 2017 | 19 | 1.160 |
Why?
| | Lymphoma, T-Cell, Peripheral | 3 | 2022 | 9 | 1.050 |
Why?
| | Epstein-Barr Virus Infections | 4 | 2018 | 81 | 0.920 |
Why?
| | Lymphoma, B-Cell | 3 | 2022 | 99 | 0.920 |
Why?
| | Graft vs Host Disease | 5 | 2020 | 232 | 0.910 |
Why?
| | Smiling | 1 | 2021 | 6 | 0.890 |
Why?
| | DNA, Viral | 3 | 2017 | 396 | 0.790 |
Why?
| | Face | 1 | 2021 | 197 | 0.760 |
Why?
| | Natural Killer T-Cells | 1 | 2020 | 56 | 0.750 |
Why?
| | Hematology | 1 | 2019 | 13 | 0.730 |
Why?
| | B7-H1 Antigen | 1 | 2020 | 135 | 0.720 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2017 | 651 | 0.680 |
Why?
| | Heterocyclic Compounds | 2 | 2017 | 20 | 0.680 |
Why?
| | Skin Neoplasms | 4 | 2020 | 808 | 0.640 |
Why?
| | Burkitt Lymphoma | 3 | 2021 | 58 | 0.610 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2018 | 153 | 0.590 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 3 | 2022 | 89 | 0.550 |
Why?
| | Prognosis | 6 | 2021 | 3540 | 0.540 |
Why?
| | Neoplasm Proteins | 1 | 2018 | 411 | 0.540 |
Why?
| | Viral Load | 1 | 2016 | 416 | 0.530 |
Why?
| | Peripheral Blood Stem Cell Transplantation | 1 | 2014 | 24 | 0.520 |
Why?
| | Cord Blood Stem Cell Transplantation | 3 | 2020 | 94 | 0.520 |
Why?
| | Antibodies, Monoclonal | 2 | 2017 | 1266 | 0.500 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 7 | 2022 | 1401 | 0.450 |
Why?
| | Antineoplastic Agents | 6 | 2020 | 2015 | 0.440 |
Why?
| | Survival Analysis | 6 | 2020 | 1359 | 0.380 |
Why?
| | Immunoblastic Lymphadenopathy | 2 | 2022 | 2 | 0.370 |
Why?
| | Transplantation, Homologous | 4 | 2019 | 464 | 0.370 |
Why?
| | Rituximab | 5 | 2022 | 171 | 0.370 |
Why?
| | Transplantation, Autologous | 3 | 2020 | 194 | 0.370 |
Why?
| | Humans | 38 | 2022 | 117481 | 0.360 |
Why?
| | Lymphoma, Non-Hodgkin | 2 | 2020 | 84 | 0.350 |
Why?
| | Anti-HIV Agents | 1 | 2014 | 678 | 0.330 |
Why?
| | Salvage Therapy | 2 | 2019 | 136 | 0.320 |
Why?
| | Neoplasm Recurrence, Local | 5 | 2022 | 845 | 0.320 |
Why?
| | Aged | 14 | 2021 | 20243 | 0.310 |
Why?
| | Autografts | 2 | 2019 | 39 | 0.310 |
Why?
| | Middle Aged | 16 | 2021 | 28654 | 0.310 |
Why?
| | Treatment Outcome | 11 | 2022 | 9333 | 0.300 |
Why?
| | Adult | 16 | 2022 | 32104 | 0.290 |
Why?
| | Benzylamines | 2 | 2017 | 41 | 0.290 |
Why?
| | Lymphoma, B-Cell, Marginal Zone | 2 | 2015 | 15 | 0.280 |
Why?
| | Aged, 80 and over | 7 | 2021 | 6794 | 0.280 |
Why?
| | Recurrence | 5 | 2020 | 1007 | 0.270 |
Why?
| | Myeloablative Agonists | 2 | 2020 | 23 | 0.250 |
Why?
| | Disease-Free Survival | 3 | 2021 | 676 | 0.230 |
Why?
| | T-Lymphocytes | 2 | 2020 | 1787 | 0.210 |
Why?
| | Allografts | 2 | 2020 | 121 | 0.210 |
Why?
| | Male | 15 | 2021 | 60409 | 0.200 |
Why?
| | Prospective Studies | 4 | 2022 | 6420 | 0.200 |
Why?
| | Mycosis Fungoides | 1 | 2020 | 56 | 0.200 |
Why?
| | Central Nervous System Neoplasms | 1 | 2021 | 126 | 0.190 |
Why?
| | Remission Induction | 2 | 2017 | 264 | 0.190 |
Why?
| | Female | 13 | 2021 | 63228 | 0.180 |
Why?
| | Retrospective Studies | 5 | 2022 | 12318 | 0.170 |
Why?
| | Thiotepa | 1 | 2018 | 22 | 0.170 |
Why?
| | Combined Modality Therapy | 3 | 2016 | 1188 | 0.170 |
Why?
| | Cytomegalovirus Infections | 1 | 2019 | 172 | 0.170 |
Why?
| | Lymphoproliferative Disorders | 1 | 2018 | 81 | 0.160 |
Why?
| | Central Nervous System Diseases | 1 | 2018 | 64 | 0.160 |
Why?
| | Killer Cells, Natural | 1 | 2020 | 312 | 0.160 |
Why?
| | Tumor Microenvironment | 1 | 2020 | 428 | 0.160 |
Why?
| | Mediastinal Neoplasms | 1 | 2017 | 34 | 0.160 |
Why?
| | Carcinogenesis | 1 | 2018 | 174 | 0.160 |
Why?
| | Asparaginase | 1 | 2016 | 32 | 0.160 |
Why?
| | Antigens, CD34 | 1 | 2017 | 88 | 0.160 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2017 | 72 | 0.150 |
Why?
| | HIV Infections | 2 | 2021 | 2510 | 0.150 |
Why?
| | Cyclophosphamide | 3 | 2022 | 236 | 0.150 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2019 | 685 | 0.150 |
Why?
| | In Situ Hybridization | 1 | 2017 | 315 | 0.150 |
Why?
| | Immunotherapy | 1 | 2020 | 476 | 0.150 |
Why?
| | Cell Count | 1 | 2017 | 323 | 0.150 |
Why?
| | Biopsy | 2 | 2018 | 1068 | 0.150 |
Why?
| | Europe | 1 | 2016 | 337 | 0.150 |
Why?
| | Neoplasm Staging | 2 | 2016 | 1216 | 0.150 |
Why?
| | Lymphoma, Large-Cell, Anaplastic | 1 | 2016 | 20 | 0.150 |
Why?
| | Immunosuppressive Agents | 1 | 2020 | 689 | 0.150 |
Why?
| | North America | 1 | 2016 | 269 | 0.140 |
Why?
| | Biomarkers | 2 | 2016 | 3574 | 0.140 |
Why?
| | Ohio | 1 | 2015 | 149 | 0.140 |
Why?
| | Drug Resistance | 1 | 2015 | 182 | 0.130 |
Why?
| | Hematopoietic Stem Cells | 1 | 2017 | 369 | 0.120 |
Why?
| | Practice Guidelines as Topic | 2 | 2020 | 1524 | 0.120 |
Why?
| | B-Lymphocytes | 1 | 2018 | 814 | 0.120 |
Why?
| | Medicare | 1 | 2018 | 718 | 0.120 |
Why?
| | Academic Medical Centers | 1 | 2015 | 414 | 0.120 |
Why?
| | Genomics | 1 | 2017 | 533 | 0.110 |
Why?
| | Young Adult | 5 | 2021 | 11069 | 0.110 |
Why?
| | Gene Expression | 1 | 2017 | 1517 | 0.110 |
Why?
| | Skin | 1 | 2016 | 692 | 0.110 |
Why?
| | Etoposide | 2 | 2022 | 160 | 0.100 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2017 | 1193 | 0.100 |
Why?
| | United States | 4 | 2021 | 12756 | 0.100 |
Why?
| | Doxorubicin | 2 | 2022 | 305 | 0.100 |
Why?
| | Melphalan | 2 | 2020 | 32 | 0.100 |
Why?
| | Biomarkers, Tumor | 1 | 2017 | 1048 | 0.100 |
Why?
| | Follow-Up Studies | 2 | 2019 | 4914 | 0.100 |
Why?
| | Gene Expression Profiling | 1 | 2017 | 1594 | 0.100 |
Why?
| | Vidarabine | 2 | 2020 | 27 | 0.090 |
Why?
| | Whole-Body Irradiation | 2 | 2020 | 77 | 0.090 |
Why?
| | Fetal Blood | 2 | 2020 | 262 | 0.080 |
Why?
| | Registries | 3 | 2020 | 1966 | 0.080 |
Why?
| | Kaplan-Meier Estimate | 2 | 2021 | 897 | 0.080 |
Why?
| | Cohort Studies | 3 | 2021 | 5106 | 0.070 |
Why?
| | Disease Management | 2 | 2018 | 602 | 0.060 |
Why?
| | Vincristine | 1 | 2022 | 106 | 0.060 |
Why?
| | Antigens, CD19 | 1 | 2022 | 99 | 0.060 |
Why?
| | Prednisone | 1 | 2022 | 248 | 0.050 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2021 | 120 | 0.050 |
Why?
| | United Kingdom | 1 | 2021 | 243 | 0.050 |
Why?
| | Busulfan | 1 | 2020 | 17 | 0.050 |
Why?
| | Immunotherapy, Adoptive | 1 | 2022 | 180 | 0.050 |
Why?
| | Aminoquinolines | 1 | 2020 | 20 | 0.050 |
Why?
| | Carmustine | 1 | 2020 | 51 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2021 | 122 | 0.050 |
Why?
| | Gene Rearrangement | 1 | 2021 | 158 | 0.050 |
Why?
| | Cytarabine | 1 | 2020 | 59 | 0.050 |
Why?
| | Acetates | 1 | 2019 | 109 | 0.040 |
Why?
| | Central Nervous System | 1 | 2021 | 262 | 0.040 |
Why?
| | Treatment Failure | 1 | 2020 | 339 | 0.040 |
Why?
| | Viral Tropism | 1 | 2018 | 25 | 0.040 |
Why?
| | Ganciclovir | 1 | 2018 | 45 | 0.040 |
Why?
| | Virus Activation | 1 | 2018 | 81 | 0.040 |
Why?
| | Virus Latency | 1 | 2018 | 77 | 0.040 |
Why?
| | Zidovudine | 1 | 2018 | 80 | 0.040 |
Why?
| | Guidelines as Topic | 1 | 2020 | 282 | 0.040 |
Why?
| | Quinazolines | 1 | 2019 | 246 | 0.040 |
Why?
| | Stem Cell Transplantation | 1 | 2019 | 146 | 0.040 |
Why?
| | Adolescent | 3 | 2022 | 18875 | 0.040 |
Why?
| | Standard of Care | 1 | 2016 | 88 | 0.040 |
Why?
| | Dexamethasone | 1 | 2018 | 304 | 0.040 |
Why?
| | Positron-Emission Tomography | 1 | 2017 | 273 | 0.040 |
Why?
| | Multivariate Analysis | 1 | 2020 | 1585 | 0.040 |
Why?
| | Mice, Inbred BALB C | 1 | 2018 | 1253 | 0.040 |
Why?
| | Organ Transplantation | 1 | 2018 | 175 | 0.040 |
Why?
| | Receptors, Interleukin-6 | 1 | 2015 | 37 | 0.040 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2016 | 66 | 0.040 |
Why?
| | Steroids | 1 | 2015 | 142 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2016 | 286 | 0.030 |
Why?
| | Antiviral Agents | 1 | 2019 | 650 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2018 | 1755 | 0.030 |
Why?
| | Databases, Factual | 1 | 2018 | 1145 | 0.030 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2018 | 499 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2018 | 2805 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2015 | 1405 | 0.030 |
Why?
| | Biomedical Research | 1 | 2016 | 598 | 0.020 |
Why?
| | Age Factors | 1 | 2018 | 3221 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2018 | 3800 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2018 | 2463 | 0.020 |
Why?
| | Risk Assessment | 1 | 2016 | 3206 | 0.020 |
Why?
| | Mice | 1 | 2018 | 15530 | 0.010 |
Why?
| | Animals | 1 | 2018 | 34332 | 0.010 |
Why?
|
|
Haverkos's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|